The Corvidia Approach

Corvidia Therapeutics is a biotechnology company pioneering the next generation of cardiovascular therapies. Leveraging functional genomics, the company’s founding team has decoded previously unrecognized genetic susceptibilities within general cardiovascular populations. Corvidia’s pipeline programs precisely identify patients with unique sensitivity to specific biologic pathways, potentially allowing for the rapid development of therapies targeting those pathways. This approach confers unique concepts within the field of cardiovascular medicines and an unprecedented accelerated path-to-market. Corvidia brings together a team of distinguished scientists, experienced drug developers as the management team, and a successful group of investors. Corvidia is headquartered in the Greater Boston area.

Management Team

Board of Directors

Sylvie Grégoire – Board Chair

Sylvie Grégoire, has over 25 years of international experience in the biotech and pharmaceutical industries. Sylvie was President of Shire Human Genetic Therapies (HGT), a business unit of Shire plc that focuses on Rare Diseases. Under her leadership, the business unit grew from $300M to $1.5B. Prior to joining Shire HGT, Sylvie was Executive Chairwoman of IDM Pharma. She was previously CEO of GlycoFi, a privately held protein technology company, held executive positions at Biogen Inc., and worked at Merck & Co. in the US and abroad. Sylvie is also a non-executive member of the board of 3 public companies: Galenica, a Swiss pharmaceutical company, NovoNordisk a Danish pharmaceutical company and PerkinElmer an instrumentation and diagnostics company. She has a depth of experience in the management of commercial operations, manufacturing and regulatory affairs. Sylvie holds a Bachelor of Science degree from Laval University and a Doctoral degree from the State University of New York at Buffalo.

Michael Davidson – CEO

Graziano Seghezzi – Sofinnova Partners

Graziano Seghezzi is a Partner at Sofinnova Partners which he joined in 2006. He seeded and was on the Board of GlycoVaxyn which was sold to GlaxoSmithKline in 2015 and Omthera Pharmaceuticals which went public on Nasdaq in 2013, then was sold to AstraZeneca later that year. Graziano also seeded and is on the Board of MISSION Therapeutics (United Kingdom), Crescendo Biologics (United Kingdom) and Hookipa Biotech (Austria). He promoted and is on the Board of BiovelocITA, Italy’s first biotech accelerator. Graziano started his career in venture capital in 2001 at Sofinnova Partners and then joined Index Venture in 2003. Prior to that, Graziano spent five years working in academic research at New York University’s School of Medicine, studying oncology and cardiovascular diseases. Graziano holds a degree in genetics and microbiology from the University of Pavia (Italy) and an MBA from RSM-Erasmus University (Netherlands).

Seth Harrison – Apple Tree Partners

Seth Harrison is the managing partner of Apple Tree Partners and serves as Executive Chairman of Braeburn Pharmaceuticals. He has invested in life sciences since 1991. Seth has served as founding investor, acting CEO or chairman of numerous portfolio companies. He is currently also Chairman of Tokai Pharmaceuticals, Chairman of Aileron Therapeutics and Deputy Chairman of Heartware International, all companies he founded. Prior to founding ATP, Seth was a general partner at Oak Investment Partners and earlier was a venture partner at Sevin Rosen Funds. His prior investments include: ArQule, Coelacanth, Cyrano Sciences, Gloucester Pharmaceuticals, Informed Access, SGX Pharmaceuticals, Ultracision and ViroPharma. Seth received an A.B. from Princeton University, an MD and MBA both from Columbia University and completed a surgery internship at the Presbyterian Hospital in the City of New York. From 2002 – 2010 he served on the board of the International Partnership for Microbicides, a Rockefeller Foundation/Gates Foundation sponsored public-private partnership engaged in the development of anti-HIV microbicides.

Adrien Lemoine - AstraZeneca

Adrien Lemoine is an Executive Director within AstraZeneca’s Corporate Development group, having responsibility for mergers and acquisitions, divestments, and strategic equity investments. Prior to joining AstraZeneca in 2015, Adrien was leading strategy and operations at GlaxoSmithKline’s Rare Diseases Unit and was a member of the Advisory Committee of Kurma BioFund II, a rare diseases focused venture capital fund. His earlier experience include roles of increasing responsibility at GlaxoSmithKline in commercial and portfolio analysis functions, and management roles in the strategy consulting industry advising and supporting biotechnology entrepreneurs. Adrien earned his MSc in Engineering and Physical Science in Medicine from the Imperial College (London, UK) and his Master’s degree in Engineering from Supélec (Paris, France).


Press release: (Jun 14th 2016)

Sylvie Grégoire Appointed as Chair of the Board of Directors

Press release: (Feb 16th 2016)

Corvidia Therapeutics Raises $26M Series A Financing


Seeking motivated, self directed, interested in changing the paradigm of cardiovascular diseases.
For more info contact –